enzalutamide (Xtandi) Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.
enzalutamide (Xtandi) For the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). High-risk is defined as prostate specific antigen (PSA) doubling time (PSADT) ≤10 months and PSA ≥2 ng/mL.
enzalutamide (Xtandi) Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.
enzalutamide (Xtandi) For treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
enzalutamide (Xtandi) As monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage radiotherapy.
talazoparib (Talzenna) In combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
August 2015 decisions news release The Scottish Medicines Consortium (SMC) has announced today that three new medicines have been accepted for use in NHSScotland.
March 2016 decisions news release The Scottish Medicines Consortium (SMC) has today published advice accepting three new medicines for routine use in NHSScotland.
February 2022 decisions news release Advice on six new medicines for use in conditions including a rare lung cancer caused by occupational exposure to asbestos and also for a severely disabling muscle wasting disease has today (Monday 7 February) been published by the Scottish Medicines Consortium (SMC).
October 2019 decisions news release Medicines which can be used to treat lymphoma, lung cancer, breast cancer and psoriasis have today (Monday 7 October) been accepted by the Scottish Medicines Consortium (SMC) for use by NHSScotland.
